Premium
Caída de anticuerpos en recién nacidos con infección congénita de Trypanosoma cruzi tratados con benznidazol
Author(s) -
Chippaux JeanPhilippe,
Clavijo Alejandra N. Salas,
Santalla Jose A.,
Postigo Jorge R.,
Schneider Dominique,
Brutus Laurent
Publication year - 2010
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2009.02431.x
Subject(s) - benznidazole , trypanosoma cruzi , serology , chagas disease , antibody , medicine , parasitemia , virology , immunology , parasite hosting , malaria , plasmodium falciparum , world wide web , computer science
Summary Objective To compare the drop of Chagas antibody titres between non‐infected and congenitally infected newborns treated by two doses of benznidazole, aiming at evaluating the recovery time and giving recommendations regarding serological criteria of recovery. Methods During a clinical trial, the drop of Trypanosoma cruzi antibody titres measured by ELISA tests was followed during the first year of life in congenitally infected newborns treated with different doses of benznidazole and compared to T. cruzi antibody titres in non‐parasitaemic newborns. Confirmation of recovery was given by two negative serological tests: Chagas Stat‐Pak ® (CSP) (immunochromatography) and Chagatest ® v3.0 (ELISA). Results In non‐parasitaemic infants of infected mothers, antibodies of maternal origin disappeared in <8 months while in infected infants, T. cruzi antibodies decreased more slowly and disappeared in 9–16 months allowing to confirm the recovery. All CSP tests were negative before the ninth month while about 10% of ELISA tests remained positive at the 12th month. Conclusions Recovery may be confirmed in most cases at 10 months. The CSP test was compared to Chagatest ® v3.0 ELISA and appeared to give a reliable response. The decrease rate of antibodies does not depend on treatment modes.